News Column

New Nanoparticles Findings Has Been Reported by E. Frohlich et al

June 6, 2014



By a News Reporter-Staff News Editor at Science Letter -- A new study on Nanoparticles is now available. According to news reporting out of Graz, Austria, by NewsRx editors, research stated, "The alveolar epithelium of the lung is by far the most permeable epithelial barrier of the human body. The risk for adverse effects by inhaled nanoparticles (NPs) depends on their hazard (negative action on cells and organism) and on exposure (concentration in the inhaled air and pattern of deposition in the lung)."

Our news journalists obtained a quote from the research, "With the development of advanced in vitro models, not only in vivo, but also cellular studies can be used for toxicological testing. Advanced in vitro studies use combinations of cells cultured in the air-liquid interface. These cultures are useful for particle uptake and mechanistic studies. Whole-body, nose-only, and lung-only exposures of animals could help to determine retention of NPs in the body. Both approaches also have their limitations; cellular studies cannot mimic the entire organism and data obtained by inhalation exposure of rodents have limitations due to differences in the respiratory system from that of humans. Simulation programs for lung deposition in humans could help to determine the relevance of the biological findings."

According to the news editors, the research concluded: "Combination of biological data generated in different biological models and in silico modeling appears suitable for a realistic estimation of potential risks by inhalation exposure to NPs."

For more information on this research see: Toxicological Assessment of Inhaled Nanoparticles: Role of in Vivo, ex Vivo, in Vitro, and in Silico Studies. International Journal of Molecular Sciences, 2014;15(3):4795-4822. International Journal of Molecular Sciences can be contacted at: Mdpi Ag, Postfach, Ch-4005 Basel, Switzerland (see also Nanoparticles).

Our news journalists report that additional information may be obtained by contacting E. Frohlich, Res Center Pharmaceut Engn GmbH, A-8010 Graz, Austria.

Keywords for this news article include: Graz, Europe, Austria, Nanotechnology, Emerging Technologies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Science Letter


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters